Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells

OBJECTIVE: Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC). Unfortunately, most patients with HCC do not respond to sorafenib, mainly because of the frequent development of drug resistance. Bilirubin is an end metabolite of heme catabolism and an indicator of liver functio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Leyi, Zhao, Qian, Yan, Ding, Lei, Ziying, Hao, Yali, Chen, Jinghong, Xue, Qian, Li, Xiaofen, Huang, Qingtian, Tang, Daolin, Dou, Q. Ping, Chen, Xin, Liu, Jinbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334754/
https://www.ncbi.nlm.nih.gov/pubmed/35604090
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334754/
https://www.ncbi.nlm.nih.gov/pubmed/35604090
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0598

Ejemplares similares